评估 QuantiFERON SARS-CoV-2 检测法以评估低和高体液免疫反应个体中 BNT162b2 mRNA COVID-19 疫苗的细胞免疫原性。
Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.
机构信息
Department of Microbiology, Ahepa University Hospital, Thessaloniki, Greece.
Department of Immunology, General Hospital G. Papanikolaou, Exohi Thessaloniki, Greece.
出版信息
Hum Vaccin Immunother. 2021 Dec 2;17(12):5148-5149. doi: 10.1080/21645515.2021.1991710. Epub 2021 Oct 29.
Abstract
Vaccines against SARS-CoV-2 are known to be less immunogenic for some individuals, whereas others present notably high levels of antibody production. We assessed the cellular response to BNT162b2 among individuals with low post-vaccination antibody levels as well as in a small group of individuals with high titers. Antibody levels were assessed by the Abbott SARS-CoV-2 IgG II Quant assay. The interferon-γ production of T-cells in response to SARS-CoV-2 antigens was determined using Qiagen's QuantiFERON SARS-CoV-2 ELISA test. Our results showed that participants with high antibody levels presented adequate cellular response in all studied cases, whereas those with low antibody levels generally showed limited to almost absent cellular response five months post vaccination.
摘要
已知针对 SARS-CoV-2 的疫苗对某些个体的免疫原性较低，而另一些个体则产生明显高水平的抗体。我们评估了 BNT162b2 在抗体水平低的个体以及少数高滴度个体中的细胞反应。抗体水平通过 Abbott SARS-CoV-2 IgG II Quant 测定法评估。使用 Qiagen 的 QuantiFERON SARS-CoV-2 ELISA 测试来确定 T 细胞对 SARS-CoV-2 抗原的干扰素-γ产生情况。我们的结果表明，在所有研究病例中，高抗体水平的参与者均表现出充分的细胞反应，而抗体水平低的参与者在接种疫苗五个月后通常表现出有限至几乎不存在的细胞反应。
相似文献
1
Evaluation of the QuantiFERON SARS-CoV-2 assay to assess cellular immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in individuals with low and high humoral response.评估 QuantiFERON SARS-CoV-2 检测法以评估低和高体液免疫反应个体中 BNT162b2 mRNA COVID-19 疫苗的细胞免疫原性。
Hum Vaccin Immunother. 2021 Dec 2;17(12):5148-5149. doi: 10.1080/21645515.2021.1991710. Epub 2021 Oct 29.
2
Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.BNT162b2 mRNA COVID-19 疫苗的抗体反应动力学：7 个月随访研究。
Medicina (Kaunas). 2021 Dec 5;57(12):1330. doi: 10.3390/medicina57121330.
3
Evaluation of T cell responses with the QuantiFERON SARS-CoV-2 assay in individuals with 3 doses of BNT162b2 vaccine, SARS-CoV-2 infection, or hybrid immunity.评估接受三剂 BNT162b2 疫苗、SARS-CoV-2 感染或混合免疫的个体中使用 QuantiFERON SARS-CoV-2 测定的 T 细胞反应。
Diagn Microbiol Infect Dis. 2023 Jul;106(3):115948. doi: 10.1016/j.diagmicrobio.2023.115948. Epub 2023 Mar 30.
4
Humoral immune response after different SARS-CoV-2 vaccination regimens.不同 SARS-CoV-2 疫苗接种方案后的体液免疫应答。
BMC Med. 2022 Jan 21;20(1):31. doi: 10.1186/s12916-021-02231-x.
5
Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.BNT162b2 和 mRNA-1273 两种 SARS-CoV-2 疫苗接种后的 IgG 抗体反应差异。
Microbiol Spectr. 2021 Dec 22;9(3):e0116221. doi: 10.1128/Spectrum.01162-21. Epub 2021 Nov 10.
6
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
7
Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.老年人接种两剂 BNT162b2 mRNA 疫苗后对 SARS-CoV-2 的功能性 T 细胞反应受损。
Front Immunol. 2021 Nov 16;12:778679. doi: 10.3389/fimmu.2021.778679. eCollection 2021.
8
Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.意大利米兰一家 COVID-19 转诊医院的医护人员中既往感染状况对 BNT162b2 mRNA COVID-19 疫苗抗体反应的影响。
Hum Vaccin Immunother. 2021 Dec 2;17(12):4747-4754. doi: 10.1080/21645515.2021.2002639. Epub 2022 Jan 27.
9
Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.韩国医护人员接种第二剂 BNT162b2 mRNA 疫苗 6 个月后仍保持对 SARS-CoV-2 的抗体应答。
Front Immunol. 2022 Jan 31;13:827306. doi: 10.3389/fimmu.2022.827306. eCollection 2022.
10
Evaluation of Three Anti-SARS-CoV-2 Serologic Immunoassays for Post-Vaccine Response.评价三种抗 SARS-CoV-2 血清学免疫分析方法在疫苗接种后的反应。
J Appl Lab Med. 2022 Jan 5;7(1):57-65. doi: 10.1093/jalm/jfab087.
引用本文的文献
1
Humoral and cellular response to SARS-CoV-2 mRNA vaccine in paediatric heart transplant recipients.儿童心脏移植受者对SARS-CoV-2 mRNA疫苗的体液和细胞反应。
Heliyon. 2024 Dec 31;11(1):e41584. doi: 10.1016/j.heliyon.2024.e41584. eCollection 2025 Jan 15.
2
QuantiFERON SARS-CoV-2 assay for the evaluation of cellular immunity after immunization with mRNA SARS-CoV-2 vaccines: a systematic review and meta-analysis.用于评估mRNA新冠病毒疫苗免疫后细胞免疫的新冠病毒定量干扰素检测：一项系统评价和荟萃分析
Immunol Res. 2024 Dec 27;73(1):25. doi: 10.1007/s12026-024-09570-w.
3
Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020-2022): A retrospective longitudinal SARS-CoV-2 serological surveillance.2020-2022 年医护人员中 BNT162b2 mRNA 疫苗的长期随访：一项回顾性纵向 SARS-CoV-2 血清学监测研究。
Hum Vaccin Immunother. 2023 Aug;19(2):2258632. doi: 10.1080/21645515.2023.2258632. Epub 2023 Sep 19.
4
The Importance of Measuring SARS-CoV-2-Specific T-Cell Responses in an Ongoing Pandemic.在持续的大流行中测量新冠病毒特异性T细胞反应的重要性。
Pathogens. 2023 Jun 22;12(7):862. doi: 10.3390/pathogens12070862.
5
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects.细胞和体液免疫反应的整合作为健康和脆弱人群中 SARS-CoV-2 疫苗接种的免疫监测工具。
Viruses. 2023 May 30;15(6):1276. doi: 10.3390/v15061276.
6
Improved Performance of the QuantiFERON-SARS-CoV-2 Assay with the Extended Set.扩展集可提高 QuantiFERON-SARS-CoV-2 检测的性能。
Viruses. 2023 May 17;15(5):1179. doi: 10.3390/v15051179.
7
Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers.医护人员接种BNT162b2疫苗九个月后的体液和细胞反应及相关变量
J Clin Med. 2023 Apr 28;12(9):3172. doi: 10.3390/jcm12093172.
8
Evaluation of QuantiFERON SARS-CoV-2 interferon-γ release assay following SARS-CoV-2 infection and vaccination.评价 SARS-CoV-2 感染和接种疫苗后，QuantiFERON SARS-CoV-2 干扰素-γ 释放检测。
Clin Exp Immunol. 2023 Jun 5;212(3):249-261. doi: 10.1093/cei/uxad027.
9
Assessing anti-SARS-CoV-2 cellular immunity in 571 vaccines by using an IFN-γ release assay.使用 IFN-γ 释放 assay 评估 571 种疫苗中的抗 SARS-CoV-2 细胞免疫。
Eur J Immunol. 2022 Dec;52(12):1961-1971. doi: 10.1002/eji.202249794. Epub 2022 Oct 28.
10
Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4 and CD8 T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay.仅供研究使用的 QuantiFERON SARS-CoV-2 检测的准确性以及 CD4 和 CD8 T 细胞-SARS-CoV-2 反应的特征：与自制的干扰素-γ 释放检测的比较。
Int J Infect Dis. 2022 Sep;122:841-849. doi: 10.1016/j.ijid.2022.07.049. Epub 2022 Jul 22.
本文引用的文献
1
Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients.在实体器官移植受者中，同源和异源mRNA及载体型新冠疫苗接种方案后，细胞免疫比体液免疫占优势。
Am J Transplant. 2021 Dec;21(12):3990-4002. doi: 10.1111/ajt.16818. Epub 2021 Sep 6.
2
Preliminary Evaluation of QuantiFERON SARS-CoV-2 and QIAreach Anti-SARS-CoV-2 Total Test in Recently Vaccinated Individuals.近期接种疫苗个体中QuantiFERON SARS-CoV-2和QIAreach抗SARS-CoV-2总检测的初步评估
Infect Dis Ther. 2021 Dec;10(4):2765-2776. doi: 10.1007/s40121-021-00521-8. Epub 2021 Aug 25.
3
The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis.罗曼诺夫研究发现，在接受维持性血液透析且未接触过病毒的患者中，对新冠病毒mRNA疫苗的体液免疫和细胞免疫反应受损。
Kidney Int. 2021 Oct;100(4):928-936. doi: 10.1016/j.kint.2021.07.005. Epub 2021 Jul 18.
4
The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses.测量严重急性呼吸综合征冠状病毒2特异性T细胞反应的潜在临床应用价值。
Clin Microbiol Infect. 2021 Dec;27(12):1784-1789. doi: 10.1016/j.cmi.2021.07.005. Epub 2021 Jul 10.
5
Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany.德国老年人对 BNT162b2 疫苗接种的迟发性抗体和 T 细胞反应。
Emerg Infect Dis. 2021 Aug;27(8):2174-2178. doi: 10.3201/eid2708.211145. Epub 2021 Jun 8.
6
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.甲氨蝶呤会削弱免疫介导的炎症性疾病患者对BNT162b2 mRNA新冠疫苗的免疫原性。
Ann Rheum Dis. 2021 Oct;80(10):1339-1344. doi: 10.1136/annrheumdis-2021-220597. Epub 2021 May 25.
7
Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).医护人员接种两剂 SARS-CoV-2 mRNA 疫苗（BNT162b2）后的早期抗体反应。
Clin Microbiol Infect. 2021 Sep;27(9):1351.e5-1351.e7. doi: 10.1016/j.cmi.2021.05.004. Epub 2021 May 8.
8
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.BNT162b2 mRNA新冠疫苗在慢性淋巴细胞白血病患者中的疗效
Blood. 2021 Jun 10;137(23):3165-3173. doi: 10.1182/blood.2021011568.
9
Humoral and Cellular Immunogenicity of the BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine in Nursing Home Residents.BNT162b2信使核糖核酸2019冠状病毒病疫苗在疗养院居民中的体液免疫原性和细胞免疫原性
Clin Infect Dis. 2021 Dec 6;73(11):2145-2147. doi: 10.1093/cid/ciab300.
10
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.mRNA 疫苗诱导的针对 SARS-CoV-2 和循环变异株的抗体。
Nature. 2021 Apr;592(7855):616-622. doi: 10.1038/s41586-021-03324-6. Epub 2021 Feb 10.
Zotero 插件